CSL gains 0.8% after Jefferies raises price target on Alentis licensing deal

Shares of Australia's CSL rose as much as 0.8% to A$178.340 after Jefferies raised its price target to A$161.50 from A$146.50 following a licensing deal with Alentis Therapeutics.